Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
10 evidence topics · 11 sources
Endotypic predictors of complete response to atomoxetine plus oxybutynin, AHI with 3% desaturation or arousal hypopnea rule
“Hypopneas were defined as a reduction in flow ≥ 30% from baseline, lasting at least 10 s, and associated with an arousal from sleep or an oxyhemoglobin desaturation ≥ 3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Figure 5 shows individual data: eight of 14 subjects had a complete response to ato-oxy (50% reduction in AHI from placebo and AHI on drug < 10 events/h). These data show that patients with an AHI on placebo < 40 events/h, Fhypopneas > 65%, and Vpassive > 55% were associated with the best likelihood of complete response on ato-oxy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MARIPOSA post hoc subgroups, AHI with 4% desaturation hypopnea rule
“Post hoc analyses showed no statistically significant differences in AHI4 reduction between subgroups based on age, sex, obesity, or baseline OSA severity (Tables E4–E7 in the online supplement). However, a higher proportion of participants with a baseline AHI4 in the mild to moderate range (AHI4 10–30 events/h) experienced a resolution of OSA (defined as AHI4 <10 events/h) compared with those with a baseline AHI4 in the severe range (AHI4 ⩾30; 52.2% vs. 7%; P = 0.004; Figure E2 in the online supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SynAIRgy prespecified subgroups by sex, severity, and BMI, AHI with 4% desaturation hypopnea rule
“Similar improvements in AHI at week 26 were observed among participants in the AD109 arm across various subgroups including sex, baseline OSA severity categories (mild, moderate, and severe), and BMI classes (Figure S3). AD109 treatment effects on AHI were consistent across estimands, with larger effect sizes observed in the supportive on-treatment estimand in participants who tolerated treatment (Table 3, Figure 2D and E, Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled phase 3 analysis: subgroups by baseline severity under both estimands and by BMI under the on-treatment estimand, AHI with 4% desaturation hypopnea rule
Pooled phase 3 analysis: patient-reported outcomes by baseline sleepiness, treatment policy and on-treatment estimands
Variability in response and symptomatic benefit confined to subgroups in an editorial on SynAIRgy
Atomoxetine plus oxybutynin in Japanese participants: responders within a null trial
“The values of AHI, nadir SpO2 , 3% oxygen desaturation index (ODI), 4% ODI, and SpO2 drop time of <90% did not significantly differ between patients receiving ATO-OXY administration and no medication.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the subanalysis demonstrated an obvious decrease in AHI in five responder patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Future studies for identifying treatment response group characteristics are warranted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine plus oxybutynin for 30 days in predominantly severe OSA, AHI with 3% and 4% desaturation hypopnea rules
“Thirty-nine people with predominantly severe OSA received 80/5 mg ato-oxy, 40/5 mg ato-oxy, 40/2.5 mg ato-oxy, or placebo nightly for 30 days in a double-blind, randomized, parallel design.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Apnea-hypopnea index (AHI) with 4% oxygen desaturation and hypoxic burden decreased by ∼50% with 80/5 mg ato-oxy from baseline but not versus placebo (e.g., AHI with 3% oxygen desaturation and AHI with 4% oxygen desaturation difference at Night 30 was -8.2 [95% confidence interval, -22.5 to 6.2] and -8.5 [95% confidence interval, -18.3 to 1.3] events/h, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence as a modifier of cardiovascular benefit with positive airway pressure
“The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote